SOUTH SAN FRANCISCO (dpa-AFX) - Genprex, Inc. (GNPX), a clinical-stage gene therapy company focused on cancer and diabetes, announced Wednesday the expansion of multiple clinical trial sites for its Acclaim-3 clinical study of Reqorsa Therapy in combination with Genentech's Tecentriq to treat extensive-stage small cell lung cancer or ES-SCLC.
In pre-market activity on the Nasdaq, Genprex shares were gaining around 7.7 percent to trade at $3.06.
Through its collaboration agreement with a large network of integrated, community-based oncology practices, the company said it has added multiple clinical trial sites for the trial.
ES-SCLC is an aggressive form of lung cancer that is presently incurable. ES-SCLC has a median progression free survival or PFS of 5.4 months from the start of initial therapy. However, once patients start receiving maintenance therapy with Tecentriq they have a median PFS of only 2.6 months.
It is expected that the combination of REQORSA and Tecentriq as maintenance therapy may provide a new therapeutic option for the treatment of small cell lung cancer.
Genprex has received U.S. Food and Drug Administration Ophran Drug and Fast Track designations for the Acclaim-3 patient population.
For More Such Health News, visit rttnews.com
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
